Recurrent Ovarian Cancer Clinical Trials

A listing of Recurrent Ovarian Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 6 clinical trials
  • 31 views
  • 04 Oct, 2022
  • 127 locations
Salvage Systemic Therapy With or Without Stereotactic Ablative Radiotherapy for Recurrent Ovarian Cancer (SABR-ROC)

effects with the introduction of taxane. Efforts have been made to find the role of salvage radiation therapy (RT) in recurrent ovarian cancer. Involved field radiotherapy (IFRT) emerged to cover the

  • 0 views
  • 04 Oct, 2022
  • 1 location
  • 0 views
  • 27 Oct, 2022
  • 1 location
A Phase Ib/II, Open-label Clinical Study to Evaluate the Safety, Tolerability and Antitumor Activities of IN10018 in Combination With Standard Chemotherapy in Subjects With High-grade Serous Epithelial Ovarian Cancer

This is a phase Ib/II, open label clinical study to evaluate the safety, tolerability and antitumor activities of IN10018 in combination with standard chemotherapy in subjects with high-grade serous ovarian cancer (including fallopian tube cancer and primary peritoneum cancer, collectively defined as ovarian cancer).

  • 0 views
  • 10 Oct, 2022
  • 5 locations
TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

This is a randomized pilot trial of weekly paclitaxel and bevacizumab with or without zoledronic acid in women with platinum-resistant epithelial ovarian cancer with 1-2 prior regimens for recurrence.

platelet count
undifferentiated carcinoma
ovarian cancer
bevacizumab
adenocarcinoma
  • 0 views
  • 04 Oct, 2022
  • 1 location
A Phase II Study of Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

This study is a phase II clinical trial evaluating a combination therapy of Oregovomab and non-platinum anti-cancer drugs in patients with PARP inhibitor-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that is not suitable for platinum retreatment

  • 0 views
  • 28 Oct, 2022
  • 1 location